Pain Management in Cancer Patients

  • Hrachya Nersesyan
  • Jeffrey J. Mucksavage
  • Eljim Tesoro
  • Konstantin V. Slavin
Part of the Cancer Growth and Progression book series (CAGP, volume 13)


Cancer is one of the most debilitating and deadly diseases that, broadly speaking, shows no preference for demographic, sex, age, or culture. It is the second leading cause of mortality of all Americans as a single disease [1], and the sheer potential for mortality from cancer can be a horrifying experience for anyone bearing this diagnosis. Pain is probably one of the most common of all cancer symptoms and can be very frightening for patients and their families. According to statistics published by the American Cancer Society in 2002 [2], 50–70% of patients with cancer experience pain, which usually only intensifies as the disease progresses. It was estimated that less than half of cancer patients get adequate relief of their pain, and 25% actually die in pain [3]. This is particularly disappointing because the pain endured by 90% of these patients could have been well managed with relatively simple interventions [4]. This chapter will discuss different options for treating cancer pain focusing on the pharmacological agents and surgical modalities currently available for pain management.


Neuropathic Pain Pain Control Cancer Pain Immediate Release Breakthrough Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Centers for Disease Control and Prevention (2007) Leading causes of death reports. CDC Report website.
  2. 2.
    American Cancer Society (2002) Cancer facts and figures 2002, p 41Google Scholar
  3. 3.
    AHCPR (1994) Clinical practice guideline #9: management of cancer pain. (Publication #94-0592). Department of Health and Human Services, Washington, DCGoogle Scholar
  4. 4.
    Friedman LL, Rodgers PE (2004) Pain management in palliative care. Clin Family Pract 6(2):371CrossRefGoogle Scholar
  5. 5.
    Valdimarsdottir U et al (2002) The unrecognized cost of cancer patients’ unrelieved symptoms: a nationwide follow-up of their surviving partners. Br J Cancer 86:1540–1545PubMedCrossRefGoogle Scholar
  6. 6.
    Winslow M, Seymour J, Clark D (2005) Stories of cancer pain: a historical perspective. J Pain Symptom Manage 29(1):22–31PubMedCrossRefGoogle Scholar
  7. 7.
    Zorza R, Zorza V (1980) A way to die. Andre Deutsch, LondonGoogle Scholar
  8. 8.
    Cherny NJ (2000) The management of cancer pain. CA Cancer J Clin 50:70–116PubMedCrossRefGoogle Scholar
  9. 9.
    Noble B et al (2005) The measurement of pain, 1945–2000. J Pain Symptom Manage 29:14–21PubMedCrossRefGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network (2000) NCCN practice guidelines for cancer pain. Oncology 14:135–150Google Scholar
  11. 11.
    Turk DC, Monarch ES, Williams AD (2002) Cancer patients in pain: considerations for assessing the whole person. Hematol Oncol Clin North Am 16:511–525PubMedCrossRefGoogle Scholar
  12. 12.
    Wong DL, Baker CM (1988) Pain in children: comparison of assessment scales. Pediatr Nurs 14:9–17PubMedGoogle Scholar
  13. 13.
    WHO (1986) Cancer pain relief. World Health Organization, GenevaGoogle Scholar
  14. 14.
    Vielhaber A, Portenoy RK (2002) Advances in cancer pain management. Hematol Oncol Clin North Am 16:527–541PubMedCrossRefGoogle Scholar
  15. 15.
    Lussier D, Huskey AG, Portenoy RK (2004) Adjuvant analgesics in cancer pain management. Oncologist 9:571–591PubMedCrossRefGoogle Scholar
  16. 16.
    Dunn MJ (1984) Nonsteroidal anti-inflammatory drugs and renal function. Ann Rev Med 35:411–428PubMedCrossRefGoogle Scholar
  17. 17.
    Rouff G, Lema M (2003) Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 25(Suppl):S21–S31CrossRefGoogle Scholar
  18. 18.
    Morales E, Mucksavage JJ (2002) Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy 22:1317–1321Google Scholar
  19. 19.
    Bombardier C et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 343:1520–1528CrossRefGoogle Scholar
  20. 20.
    Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959PubMedCrossRefGoogle Scholar
  21. 21.
    Merck (2004) Merck announces voluntary worldwide withdrawal of VIOXX®. News release. Whitehouse Station, NJ.
  22. 22.
    Singh D (2004) Merck withdraws arthritis drug worldwide. BMJ 329:816PubMedCrossRefGoogle Scholar
  23. 23.
    Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:17CrossRefGoogle Scholar
  24. 24.
    Silverstein FE et al (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284:1247–1255PubMedCrossRefGoogle Scholar
  25. 25.
    Grond S et al (1999) High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 18:174–179PubMedCrossRefGoogle Scholar
  26. 26.
    Gutstein HB, Akil H (2001) Opioid analgesics. In: Hardman JG, Limbrid E (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 569–619Google Scholar
  27. 27.
    Fukshansky M, Are M, Burton AW (2005) The role of opioids in cancer pain management. Pain Pract 5(1):43–54PubMedCrossRefGoogle Scholar
  28. 28.
    Hagen NA et al (2005) Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MSContinXL) in cancer pain. J Pain Symptom Manage 29:80–90PubMedCrossRefGoogle Scholar
  29. 29.
    Donnely S et al (2002) Morphine in cancer pain management: a practical guide. Support Care Cancer 10:13–35CrossRefGoogle Scholar
  30. 30.
    Sarhill N, Walsh D, Nelson KA (2001) Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 9:84–96PubMedCrossRefGoogle Scholar
  31. 31.
    Pereira, J et al (2001) Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 22:672–687PubMedCrossRefGoogle Scholar
  32. 32.
    Korte W, Stoutz N, Morant R (1996) Day-to-day titration to initiate transdermal fentanyl in cancer patients: short- and long-term experience in a prospective study of 39 patients. J Pain Symptom Manage 11:139–146PubMedCrossRefGoogle Scholar
  33. 33.
    Coluzzi PH et al (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91:123–130PubMedCrossRefGoogle Scholar
  34. 34.
    Burton AW et al (2004) Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises. Clin J Pain 20:195–197PubMedCrossRefGoogle Scholar
  35. 35.
    Budd K (2003) Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract 133:9–14Google Scholar
  36. 36.
    Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629–2638PubMedCrossRefGoogle Scholar
  37. 37.
    Evans HC, Easthope SE (2003) Transdermal buprenotphine. Drugs 63(19):1999–2010PubMedCrossRefGoogle Scholar
  38. 38.
    Heiskanen TE et al (2000) Morphine or oxycodone in cancer pain? Acta Oncologica 39:941–947PubMedCrossRefGoogle Scholar
  39. 39.
    Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73–83PubMedCrossRefGoogle Scholar
  40. 40.
    Berland D (2000) Pain management in patients with advanced cancer. Ann Intern Med 132:593PubMedGoogle Scholar
  41. 41.
    Lawlor PG et al (1998) Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82:1167–1173PubMedCrossRefGoogle Scholar
  42. 42.
    Ripamonti C et al (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216–3221PubMedGoogle Scholar
  43. 43.
    Kannan TR et al (2002) Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 23:60–65PubMedCrossRefGoogle Scholar
  44. 44.
    Mercadante S et al (2000) Analgesic effects of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000(20)Google Scholar
  45. 45.
    Balducci L (2003) Management of cancer pain in geriatric patients. J Support Oncol 1(3):175–191PubMedGoogle Scholar
  46. 46.
    Collins SL et al (2000) Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 20:449–458PubMedCrossRefGoogle Scholar
  47. 47.
    Onghena P, van Houdenhove B (1992) Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 49:205–219PubMedCrossRefGoogle Scholar
  48. 48.
    Watson CP (2000) The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 16(Suppl 2):49–55Google Scholar
  49. 49.
    Magni G, Arsie D, De Leo D (1987) Antidepressants in the treatment of cancer pain: a survey in Italy. Pain 29:347–353PubMedCrossRefGoogle Scholar
  50. 50.
    Walsh TD (1986) Controlled study of imipramine and morphine in chronic pain due to advanced cancer. Proc Am Soc Clin Oncol 5:237Google Scholar
  51. 51.
    Glassman AH, Bigger JT (1981) Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatr 38:815–820PubMedGoogle Scholar
  52. 52.
    Masand PS, Gupta S (1999) Selective serotonin-reuptake inhibitors: an update. Harvard Rev Psychiatr 52:547–552Google Scholar
  53. 53.
    Sindrup SH et al (1990) The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42(2):135–144PubMedCrossRefGoogle Scholar
  54. 54.
    Sindrup SH et al (1992) The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 52(5):547–552PubMedCrossRefGoogle Scholar
  55. 55.
    Sindrup SH et al (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60(8):1284–1289PubMedGoogle Scholar
  56. 56.
    Backonja MM (2000) Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 16(Suppl 6):67–72Google Scholar
  57. 57.
    Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 6A:61–68CrossRefGoogle Scholar
  58. 58.
    Rice AS, Maton S (2001) Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study. Pain 94:215–224PubMedCrossRefGoogle Scholar
  59. 59.
    Rowbotham M et al (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280:1837–1842PubMedCrossRefGoogle Scholar
  60. 60.
    Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes: mechanism of action and place in therapy. Drugs 60:1029–1052PubMedCrossRefGoogle Scholar
  61. 61.
    Caraceni A et al (1999) Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17:441–445PubMedCrossRefGoogle Scholar
  62. 62.
    Oneschuk D, al-Shahri MZ (2003) The pattern of gabapentin use in a tertiary palliative care unit. J Palliat Care 195:185–187Google Scholar
  63. 63.
    Caraceni A et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin cancer pain study group. J Clin Oncol 22(14):2909–2917PubMedCrossRefGoogle Scholar
  64. 64.
    Dworkin RH et al (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524–1534PubMedCrossRefGoogle Scholar
  65. 65.
    Yajnik S et al (1992) Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage 7:209–230PubMedCrossRefGoogle Scholar
  66. 66.
    Vestergaard K et al (2001) Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56:184–190PubMedGoogle Scholar
  67. 67.
    Zakrzewska JM et al (1997) Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 73:223–230PubMedCrossRefGoogle Scholar
  68. 68.
    Dworkin RH et al (2003) Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60:1274–1283PubMedGoogle Scholar
  69. 69.
    Price MJ (2004) Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 20:33–36PubMedCrossRefGoogle Scholar
  70. 70.
    Ettinger AB, Portenoy RK (1988) The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3:99–103PubMedCrossRefGoogle Scholar
  71. 71.
    Greenberg HS, Kim JH, Posner JB (1980) Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 8:361–366PubMedCrossRefGoogle Scholar
  72. 72.
    Watanabe S, Bruera E (1994) Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 9:442–445PubMedCrossRefGoogle Scholar
  73. 73.
    Farr WC (1990) The use of corticosteroids for symptom management in terminally ill patients. Am J Hosp Care 7:41–46PubMedCrossRefGoogle Scholar
  74. 74.
    Mercadante S, Fulfaro F, Casuccio A (2001) The use of corticosteroids in home palliative care. Support Care Cancer 9:386–389PubMedCrossRefGoogle Scholar
  75. 75.
    Khojainova N et al (2002) Olanzapine in the management of cancer pain. J Pain Symptom Manage 23:346–350PubMedCrossRefGoogle Scholar
  76. 76.
    Dalal S, Melzack R (1998) Potentiation of opioid analgesia by psychostimulant drugs: a review. J Pain Symptom Manage 16:245–253PubMedCrossRefGoogle Scholar
  77. 77.
    Rozans M et al (2002) Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 20:335–339PubMedCrossRefGoogle Scholar
  78. 78.
    Rosen LS et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–387PubMedGoogle Scholar
  79. 79.
    Serafini AN (2001) Therapy of metastatic bone pain. J Nucl Med 42:895–906PubMedGoogle Scholar
  80. 80.
    Roth A, Kolaric K (1986) Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer: results of a controlled randomized study. Oncology 43:283–287PubMedCrossRefGoogle Scholar
  81. 81.
    Szanto J, Ady N, Jozsef S (1992) Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 49:180–182PubMedCrossRefGoogle Scholar
  82. 82.
    Slavin KV, Tesoro EP, Mucksavage JJ (2004) The treatment of cancer pain. Drugs Today 40(3):235–245PubMedCrossRefGoogle Scholar
  83. 83.
    Eisenach JC et al (1995) Epidural clonidine analgesia for intractable cancer pain. The epidural clonidine study group. Pain 61:391–399PubMedCrossRefGoogle Scholar
  84. 84.
    Pud D et al (1998) The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo-controlled trial. Pain 75:349–354PubMedCrossRefGoogle Scholar
  85. 85.
    Jones B et al (2003) Is there still a role for open cordotomy in cancer pain management? J Pain Symptom Manage 25:179–184PubMedCrossRefGoogle Scholar
  86. 86.
    Nauta HJ et al (2000) Punctate midline myelotomy for the relief of visceral cancer pain. J Neurosurg 92(Suppl 2):125–130PubMedGoogle Scholar
  87. 87.
    Whittle IR, Jenkinson JL (1995) CT-guided stereotactic antero-medial pulvinotomy and centromedian-parafascicular thalamotomy for intractable malignant pain. Br J Neurosurg 9:195–200PubMedCrossRefGoogle Scholar
  88. 88.
    Wong ET et al (1997) Palliation of intractable cancer pain by MRI-guided cingulotomy. Clin J Pain 13:260–263PubMedCrossRefGoogle Scholar
  89. 89.
    Kanpolat Y et al (1995) CT-guided pain procedures for intractable pain in malignancy. Acta Neurochir Suppl (Wien) 64:88–91Google Scholar
  90. 90.
    Taub E (2003) Spinal cord stimulation for cancer-related pain: a neglected indication? Quadrennial Meeting Am Soc Stereotactic Funct Neurosurg, New York (May 18–21). p 52Google Scholar
  91. 91.
    Rauck RL et al (2003) Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain Symptom Manage 4(8):441–447Google Scholar
  92. 92.
    Smith TJ et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040–4049PubMedCrossRefGoogle Scholar
  93. 93.
    Slavin KV, Hsu FPK, Fessler RG (2002) Intrathecal opioids: intrathecal drug-delivery systems. In: Burchiel KJ (eds) Surgical management of pain. Thieme, New York, pp 603–613Google Scholar
  94. 94.
    Dews TE, Mekhail N (2004) Safe use of opioids in chronic noncancer pain. Cleve Clin J Med 71(11):897–904PubMedCrossRefGoogle Scholar
  95. 95.
    Becker R et al (2000) The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg 75:16–26PubMedCrossRefGoogle Scholar
  96. 96.
    McGivern JG, McDonough SI (2004) Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 3(6):457–478PubMedCrossRefGoogle Scholar
  97. 97.
    Miljanich GP, Ramachandran J (1995) Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 35:707–734PubMedCrossRefGoogle Scholar
  98. 98.
    Miljanich GP (2004) Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 11(23):3029–3040PubMedGoogle Scholar
  99. 99.
    Mathur V (2000) Ziconotide: a new pharmacological class of drug for the management of pain. Semin Anesth Periop Med Pain 19:67–75CrossRefGoogle Scholar
  100. 100.
    Staats PS et al (2004) Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA 291:63–70PubMedCrossRefGoogle Scholar
  101. 101.
    Doggrell SA (2004) Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 13(7):875–877PubMedCrossRefGoogle Scholar
  102. 102.
    Webster L et al (2001) (233) characterization of confusion, an adverse event associated with intrathecal ziconotide infusion in chronic pain patients. Pain Med 2(3):253–254CrossRefGoogle Scholar
  103. 103.
    Wermeling D et al (2003) Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 43(6):624–636PubMedGoogle Scholar
  104. 104.
    Slavin KV, Solko AM (2003) Intrathecal narcotics: spinal and intraventricular. In: Schulder M (eds) Handbook of stereotactic and functional neurosurgery. Marcel Dekker, New York, pp 443–457Google Scholar
  105. 105.
    Meldrum M (2005) The ladder and the clock: cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage 29:41–54PubMedCrossRefGoogle Scholar
  106. 106.
    Ahmedzai S (1997) New approaches to pain control in patients with cancer. Eur J Can 33(Suppl 6):S8–S14CrossRefGoogle Scholar
  107. 107.
    Slavin KV, Laurito C (2003) Surgical approaches to cancer pain: experience of single institution. J Pain 4(Suppl 1):90Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Hrachya Nersesyan
    • 1
  • Jeffrey J. Mucksavage
    • 2
  • Eljim Tesoro
    • 2
  • Konstantin V. Slavin
    • 3
  1. 1.Illinois Neurological Institute, OSF Saint Francis Medical CenterPeoriaUSA
  2. 2.Department of Pharmacy PracticeUniversity of Illinois at ChicagoChicagoUSA
  3. 3.Section of Functional and Stereotactic Neurosurgery, Department of NeurosurgeryUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations